search
Back to results

Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal (UH3)

Primary Purpose

Opiate Withdrawal Syndrome, Opioid Use

Status
Not yet recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
LFX/PGB
LFX/PLA-PGB
Sponsored by
University of Pennsylvania
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Opiate Withdrawal Syndrome

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Male and/or female subjects ≥ 18 years of age Meet DSM-5 criteria for an Opioid Use Disorder with physiologic features. Have met 2 or more of the 11 criteria for an OUD including tolerance and withdrawal within the last 12 months Interested in opioid antagonist treatment Used opioids in 20 or more of the last 30 days A stable address in the local area; not planning to move in the next 60 days. Have documents for ID check Absence of medical or psychiatric conditions that are likely to interfere with study participation Has 12 lead ECG demonstrating a QTc ≤450 msec and a QRS ≤120 msec. Site PI has final determination for study inclusion if readings exceed these limits. The PENN cardiologists and medical monitor are available for consultation when needed Negative pregnancy test and using adequate contraception if of childbearing potential. Exclusion Criteria: Current psychotic disorder (bipolar I, schizophrenia, major depression that is not in remission Alcohol, benzodiazepine, or other sedative use disorder with physiological features that require medication for detoxification Allergy or other serious adverse event due to treatment with pregabalin, XR-NTX, or lofexidine Pending incarceration or plans to leave the immediate area in the next 30 days Homicidal or otherwise behaviorally disturbed requiring immediate attention High risk for suicide as determined by answering 'yes' to questions 4 and/or 5 on C-SSRS Blood pressure <90 mm Hg (systolic) or <60 mm Hg (diastolic). If value out of normal range, the investigator and study Clinician will decide subject inclusion/exclusion on case-by-case basis Heart rate and/or pulse<50 bpm at screening-sitting An Estimated Glomerular Filtration Rate eGFR<70 mL/min/1.73m2 A History of, or current Seizure disorder (excluding childhood febrile seizures) Inability to read and/or understand English. For example, unable to understand the informed consent as demonstrated by failing to answer 9/10 questions correctly on the quiz 12. Pregnant or breastfeeding 13. Currently taking sympathomimetic drugs, or a thiazolidinedione antidiabetic ALT and/or AST >4X upper limit of normal A Child-Pugh score >7 Currently receiving opioids for pain management In a treatment study where medication was administered in the last 30 days Currently using medications that are known to be strong or moderate inhibitors of CYP2D6 such as fluoxetine, paroxetine, mirabegron, bupropion, quinidine, terbinafine, cimetidine, cinacalcet, duloxetine, or fluvoxamine In a methadone maintenance or buprenorphine treatment program within the last 30 days

Sites / Locations

  • University of Pennsylvania, Treatment Research Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

LFX/PGB

LFX/PLA-PGB

Arm Description

PGB/day 1=400mg, day 2-7=600mg each day, day 8=400mg, day 9=200mg, day 10=100mg LFX/day 1=1.62mg, day 2-7=2.16mg each day, day 8=1.44mg, day 9=0.72mg, day 10=0.72mg

PLA-PGB/day 1-7= 0mg each day, day 8, 9, and 10 =0mg each day LFX/ day 1=1.62mg, day 2-7=2.16mg each day, day 8=1.44mg, day 9=0.72mg, day 10=0.72mg

Outcomes

Primary Outcome Measures

Subjective Opioid Withdrawal Scale (SOWS) scores
Subjective patient reported Opioid Withdrawal measured by the SOWS, (0-30); 0 = no withdrawal/30 = severe withdrawal

Secondary Outcome Measures

Study detox completion
Proportion that receives one or more doses of study medication and completed withdrawal (Completing withdrawal management will be defined as having received at least 1 dose of study medication on day 8 and completing the SOWS-Gossop assessment on day 8); and proportion that transition to XR-NTX; adverse events
XR-NTX IM injection
proportion that receives 380mg dose of extended-release naltrexone

Full Information

First Posted
August 1, 2023
Last Updated
October 9, 2023
Sponsor
University of Pennsylvania
search

1. Study Identification

Unique Protocol Identification Number
NCT05995535
Brief Title
Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal
Acronym
UH3
Official Title
Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
November 1, 2023 (Anticipated)
Primary Completion Date
August 31, 2026 (Anticipated)
Study Completion Date
August 31, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Pennsylvania

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A placebo-controlled trial in which male and female outpatients with an opioid use disorder who express interest in extended-release injectable naltrexone (XR-NTX) are randomized 1:1 to lofexidine/pregabalin or lofexidine/pregabalin placebo for withdrawal management and offered XR-NTX if after completing withdrawal.
Detailed Description
A placebo-controlled trial in which male and female outpatients with an opioid use disorder who express interest in extended-release injectable naltrexone (XR-NTX) are randomized 1:1 to lofexidine/pregabalin or lofexidine/pregabalin placebo for withdrawal management and offered XR-NTX if after completing withdrawal. It follows a UG3 study in which 90 inpatients with an OUD who expressed interest in XR-NTX were randomized 2:1 to withdrawal management with lofexidine/pregabalin or lofexidine/placebo pregabalin. Results were that the conditions were equally safe, and that lofexidine/pregabalin was more effective in reducing subjective withdrawal and keeping patients in treatment than lofexidine/placebo pregabalin. The objectives are to study the safety and effectiveness of lofexidine/pregabalin compared to lofexidine/placebo for managing opioid withdrawal and transitioning to XR-NTX in outpatient settings.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Opiate Withdrawal Syndrome, Opioid Use

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Active pregabalin plus lofexidine versus placebo pregabalin plus lofexidine
Masking
ParticipantInvestigator
Masking Description
double-blind placebo-controlled randomized trial
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
LFX/PGB
Arm Type
Experimental
Arm Description
PGB/day 1=400mg, day 2-7=600mg each day, day 8=400mg, day 9=200mg, day 10=100mg LFX/day 1=1.62mg, day 2-7=2.16mg each day, day 8=1.44mg, day 9=0.72mg, day 10=0.72mg
Arm Title
LFX/PLA-PGB
Arm Type
Active Comparator
Arm Description
PLA-PGB/day 1-7= 0mg each day, day 8, 9, and 10 =0mg each day LFX/ day 1=1.62mg, day 2-7=2.16mg each day, day 8=1.44mg, day 9=0.72mg, day 10=0.72mg
Intervention Type
Drug
Intervention Name(s)
LFX/PGB
Other Intervention Name(s)
Lucemyra, lyrica
Intervention Description
lofexidine tablets 0.18mg tabs pregabalin capsules 100mg and 25mg
Intervention Type
Drug
Intervention Name(s)
LFX/PLA-PGB
Other Intervention Name(s)
Lucemyra, placebo pregabalin
Intervention Description
lofexidine tablets 0.18mg tabs pregabalin capsules 0mg
Primary Outcome Measure Information:
Title
Subjective Opioid Withdrawal Scale (SOWS) scores
Description
Subjective patient reported Opioid Withdrawal measured by the SOWS, (0-30); 0 = no withdrawal/30 = severe withdrawal
Time Frame
10 days per subject, through study completion (N=150)
Secondary Outcome Measure Information:
Title
Study detox completion
Description
Proportion that receives one or more doses of study medication and completed withdrawal (Completing withdrawal management will be defined as having received at least 1 dose of study medication on day 8 and completing the SOWS-Gossop assessment on day 8); and proportion that transition to XR-NTX; adverse events
Time Frame
10 days per subject, through study completion (N=150)
Title
XR-NTX IM injection
Description
proportion that receives 380mg dose of extended-release naltrexone
Time Frame
upto 2 days per subject (N=150)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male and/or female subjects ≥ 18 years of age Meet DSM-5 criteria for an Opioid Use Disorder with physiologic features. Have met 2 or more of the 11 criteria for an OUD including tolerance and withdrawal within the last 12 months Interested in opioid antagonist treatment Used opioids in 20 or more of the last 30 days A stable address in the local area; not planning to move in the next 60 days. Have documents for ID check Absence of medical or psychiatric conditions that are likely to interfere with study participation Has 12 lead ECG demonstrating a QTc ≤450 msec and a QRS ≤120 msec. Site PI has final determination for study inclusion if readings exceed these limits. The PENN cardiologists and medical monitor are available for consultation when needed Negative pregnancy test and using adequate contraception if of childbearing potential. Exclusion Criteria: Current psychotic disorder (bipolar I, schizophrenia, major depression that is not in remission Alcohol, benzodiazepine, or other sedative use disorder with physiological features that require medication for detoxification Allergy or other serious adverse event due to treatment with pregabalin, XR-NTX, or lofexidine Pending incarceration or plans to leave the immediate area in the next 30 days Homicidal or otherwise behaviorally disturbed requiring immediate attention High risk for suicide as determined by answering 'yes' to questions 4 and/or 5 on C-SSRS Blood pressure <90 mm Hg (systolic) or <60 mm Hg (diastolic). If value out of normal range, the investigator and study Clinician will decide subject inclusion/exclusion on case-by-case basis Heart rate and/or pulse<50 bpm at screening-sitting An Estimated Glomerular Filtration Rate eGFR<70 mL/min/1.73m2 A History of, or current Seizure disorder (excluding childhood febrile seizures) Inability to read and/or understand English. For example, unable to understand the informed consent as demonstrated by failing to answer 9/10 questions correctly on the quiz 12. Pregnant or breastfeeding 13. Currently taking sympathomimetic drugs, or a thiazolidinedione antidiabetic ALT and/or AST >4X upper limit of normal A Child-Pugh score >7 Currently receiving opioids for pain management In a treatment study where medication was administered in the last 30 days Currently using medications that are known to be strong or moderate inhibitors of CYP2D6 such as fluoxetine, paroxetine, mirabegron, bupropion, quinidine, terbinafine, cimetidine, cinacalcet, duloxetine, or fluvoxamine In a methadone maintenance or buprenorphine treatment program within the last 30 days
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kyle M Kampman, MD
Phone
215-746-2764
Email
Kampman@pennmedicine.upenn.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Matthew R Taylor
Phone
215-746-0467
Email
matthew.taylor@pennmedicine.upenn.edu
Facility Information:
Facility Name
University of Pennsylvania, Treatment Research Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal

We'll reach out to this number within 24 hrs